Key result
Co-expression network analysis and clinical validation identified AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, and MGAM as potential diagnostic biomarkers for acute myocardial infarction.
Why the study?
Specific diagnostic biomarkers have not been fully established and candidate regulatory targets for AMI remain to be determined.
Population
26 patients with AMI and 21 control subjects with normal cardiac function
Comparison
AMI vs control subjects
Design
Bioinformatic co-expression network analysis and RT-qPCR validation study
Authors
Loading...
These gene changes were associated with AMI; hypothesis-generating for diagnostic biomarkers, needing prospective validation before use.
Case-Control (n=109)
No
p-value: p=<0.01
The hub genes AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, and MGAM were identified as potential novel biomarkers for the diagnosis of acute myocardial infarction.
Hu et al. (2021) conducted a case-control in Acute myocardial infarction (n=109). Acute myocardial infarction vs. Healthy controls was evaluated on Differential expression of hub genes (AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, MGAM) (p=<0.01). Co-expression network analysis and clinical validation identified AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, and MGAM as potential diagnostic biomarkers for acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: